Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.

about

The optimal combination therapy for the treatment of early rheumatoid arthritis.Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

P2860

Q38522457-71B8507E-1E85-4FBA-86B4-8D661A6B3AAA Q54962371-E5FDEDF9-0C0D-4DC6-A39E-983C3169B860

P2860

Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.

Item

http://www.wikidata.org/entity/Q38264653

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Optimizing the expediency of T ...... vity in the maintenance phase.

@en

type

Item

label

Optimizing the expediency of T ...... vity in the maintenance phase.

@en

prefLabel

Optimizing the expediency of T ...... vity in the maintenance phase.

@en

P1476

Optimizing the expediency of T ...... vity in the maintenance phase.

@en

P2093

Femke Lamers-Karnebeek

http://www.w3.org/2001/XMLSchema#string

Iris L A van Ingen

http://www.w3.org/2001/XMLSchema#string

Tim L Jansen

http://www.w3.org/2001/XMLSchema#string

P2860

The pathogenesis of rheumatoid arthritis

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

The epidemiology of rheumatoid arthritis.

Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

P304

1761-1767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2014.955009

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267762425

http://www.w3.org/2001/XMLSchema#string

P698

25366268

http://www.w3.org/2001/XMLSchema#string

Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.

about

P2860

P2860

Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698